What about Pain in Disorders of Consciousness?
Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 3
Abstract
The management and treatment of acute pain is very difficult in non-communicative patients with disorders of consciousness (i.e., vegetative state/unresponsive wakefulness syndrome (VS/UWS) and minimally conscious state), creating an ethical dilemma for caregivers and an emotional burden among both relatives and caregivers. In this review, we summarize recent findings about the neural substrates of nociception and pain in VS/UWS patients as well as recent behavioral assessment methods of nociception specifically designed for patients in altered states of consciousness. We will finally discuss implications for pain treatment in these patients.
Authors and Affiliations
C. Schnakers, C. Chatelle, A. Demertzi, S. Majerus, S. Laureys
Keywords
Related Articles
- EP ID EP681224
- DOI 10.1208/s12248-012-9346-5
- Views 79
- Downloads 0
Translational Biomarkers: from Preclinical to Clinical a Report of 2009 AAPS/ACCP Biomarker Workshop
There have been some successes in qualifying biomarkers and applying them to drug development and clinical treatment of various diseases. A recent success is illustrated by a collaborative effort among the US Food and Dr...
The Use of Modeling Tools to Drive Efficient Oral Product Design
Modeling and simulation of drug dissolution and oral absorption has been increasingly used over the last decade to understand drug behavior in vivo based on the physicochemical properties of Active Pharmaceutical Ingredi...
Immunogenicity of Subcutaneously Administered Therapeutic Proteins—a Mechanistic Perspective
The administration of therapeutic proteins via the subcutaneous route (sc) is desired for compliance and convenience, but could be challenging due to perceived immunogenic potential or unwanted immune responses. There ar...
Current Industrial Practices in Assessing CYP450 Enzyme Induction: Preclinical and Clinical
Induction of drug metabolizing enzymes, such as the cytochromes P450 (CYP) is known to cause drug-drug interactions due to increased elimination of co-administered drugs. This increased elimination may lead to significan...
Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales
The online version of this article (doi:10.1208/s12248-010-9230-0) contains supplementary material, which is available to authorized users.